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Abstract
Rationale Clozapine (CLZ) is an effective treatment for
schizophrenia, producing improvements in both negative
symptoms and cognitive impairments. Cognitive impairments
can be modelled in animals by ketamine (KET) and assessed
using the attentional set-shift task (ASST).
Objective Our first aim was to determine whether CLZ im-
proves cognitive function and reverses KET-induced cogni-
tive impairments using the ASST. Our second aim was to
assess dose dependency of these effects.
Results Our findings demonstrate that acute as well as sub-
chronic administration of KET cause cognitive deficits ob-
served as increase in number of trails and errors to reach the
criterion in the EDS phase. CLZ 0.3 mg/kg reversed the ef-
fects of both acute and sub-chronic KET, with no effects on
locomotor activity. However, clozapine’s effect after sub-
chronic administration of dose 0.3 mg/kg was not as explicit
as in the case of acute treatment. Moreover, administration of
1 mg/kg CLZ to KET-treated mice induced or enhanced def-
icits in the extra-dimensional shift phase compared to 1 mg/kg
CLZ administration to mice not receiving KET. Locomotor
activity test showed sedation effects of CLZ 1 mg/kg after
acute treatment; therefore, effect of CLZ 1 mg/kg on KET-
induced cognitive deficits was not evaluated in the attentional
set-shift task (ASST) test.
Conclusions The present findings support dose-dependent ef-
fects of CLZ to reverse KET-induced cognitive deficits. The
observed dose dependency may be mediated by activation of
different receptors, including monomers and/or heterodimers.
Keywords Cognitive deficit . Schizophrenia . Set-shifting .
Clozapine . Ketamine . Extra-dimensional
Introduction
Studying the mechanisms of action for antipsychotic drugs
requires development of new rodent models. However,
modelling symptoms of schizophrenia in animals is compli-
cated by the inability of current approaches to mimic all as-
pects of such a complex and uniquely human disorder. Most
current animal models produce behavioural changes that re-
semble the positive symptoms of schizophrenia, which prob-
ably reflect altered mesolimbic dopamine function. Some
models also include altered social interaction, as well as learn-
ing and memory impairments, which are analogous to nega-
tive and cognitive symptoms of schizophrenia, respectively
(Jones et al. 2011; Neill et al. 2014). Prefrontal cortex (PFC)
dysfunction is a major contributor to the symptoms of schizo-
phrenia, and includes impaired ability to shift perceptual at-
tentional set. Noncompetitive N-methyl-D-aspartate receptor
(NMDAR) antagonists such ketamine (KET) and phencycli-
dine (PCP) produce behavioural effects in healthy people that
resemble symptoms of schizophrenia in patients (Krystal et al.
1994; Lahti and Tamminga 1999). Moreover, acute adminis-
tration of KET or PCP rapidly increases PFC metabolic activ-
ity in parallel with PFC-related psychotic symptoms in healthy
individuals (Vollenweider et al. 1997). This observation was
adapted to an animal model of schizophrenia; acute and/or
sub-chronic treatment with KET or PCP, followed by a wash-
out period, induces cognitive impairments in animals
(Scheggia et al. 2014; Neill et al. 2010; Becker et al. 2003;
Becker and Grecksch 2004; McLean et al. 2008; Kos et al.
2011; Nikiforuk et al. 2013). Cognitive disturbances associat-
ed with schizophrenia and depression are closely related to
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dysfunctions of the prefrontal cortex, a brain region thought to
execute cognitive control over behaviour (Shallice 1988).
Attentional set shift tasks are used to assess frontal lobe dam-
age and cognitive flexibility. This kind of tasks is based on the
use of compound stimuli (i.e. texture and odour stimuli in dif-
ferent modalities). Subjects are trained to pay attention to one
dimension on the basis of positive feedback or reinforcement
and to ignore the other one, including assessing of reversal
(previously correct exemplar of the same dimension is now
incorrect and previously incorrect exemplar is now correct),
intra-dimensional shifting (novel exemplars are introduced,
but the relevant dimension is still the same) and an extra-
dimensional shift (novel exemplars are again introduced, but
now the previous dimension is irrelevant) (Keeler and Robbins
2011). In humans, the classical tests to measure cognitive abil-
ities are the Wisconsin Card Sorting Test (WCST) (Grant and
Berg 1948; Berg 1948; Eling et al. 2008) and the CANTAB ID/
ED task (Roberts et al. 1988; Dias et al. 1996), which are
examples of attentional set shift tasks. The WCST is a test of
card sorting in which presented cards to patients differ in the
colour, the shape and the numbers and patients have to match
cards not knowing the rules. Following decision about
matching stimulus cards is based on feedback whether a partic-
ular match to an exemplar is right or wrong. In the CANTAB
IED, test stimuli (different sets of shapes overlaid by lines) are
presented on a touch-sensitive screen where only one of the
shapes is initially relevant. The CANTAB test involves main
forms of cognitive flexibility—reversal learning and extra-
dimensional shift; however, WCST lets to assess extra-
dimensional (ED) shifting. Birrell and Brown (2000) adopted
ID/ED test for rodents—rats (Birrell and Brown 2000) and
mice (Bissonette et al. 2008)—using different textures and
odours as perceptual dimension. Overall, the attentional set
shift task version for rodents is now one of the main animal
tests to evaluate cognitive deficits (Barnett et al. 2010).
The first aim of our study was to determine whether the
antipsychotic, clozapine (CLZ), reverses KET-induced defi-
cits, using the ASST model. CLZ is the most effective drug
for treatment-resistant schizophrenia (Elkis and Buckley
2016), and is preferred because it lacks extrapyramidal side
effects (EPSE) and produces sustained prolactin elevation and
improvements in negative symptoms. CLZ also has a unique
antisuicidal effect. There is extensive literature regarding the
beneficial effects of CLZ for reducing cognitive deficits in
patients with schizophrenia (Hill et al. 2010). Spagna et al.
(2015) demonstrated that treatment with CLZ significantly
improves orienting, but does not alter executive control of
attention. Furthermore, CLZ has a unique mechanism of ac-
tion compared to other antipsychotic drugs (Leo and Regno
2000). Most antipsychotics produce 70% or greater dopamine
receptor 2 (D2) occupancy at clinical doses; however, CLZ
produces optimal antipsychotic efficacy with 50–60% D2 oc-
cupancy. CLZ reaches this receptor occupancy with 300–
400 ng/mL doses, and low-dose CLZ also produces complete
occupancy of serotonin 5-HT2 receptors. Moreover, CLZ has
high affinity for D4 receptors and is an antagonist at adrener-
gic, cholinergic (muscarinic, M1 and M5), histaminergic, and
serotonergic receptors (Baviera et al. 2008). The antipsychotic
effects of CLZ are associated with rapid dissociation from D2
receptors, preferential action at serotoninergic 5-HT2A and
2C receptors, 5-HT1A receptor agonism, and increased extra-
cellular levels of acetylcholine in the PFC, striatum, and nu-
cleus accumbens (Horacek et al. 2006). Moreover, low D2
occupancy may explain the absence of EPSE and sustained
prolactin elevation. Although CLZ is a very effective antipsy-
chotic, it is usually a last treatment option in patients with
schizophrenia, due to the risk of agranulocytosis. Other side
effects of CLZ include skin rashes and effects on the cardio-
vascular, nervous, and digestive systems. However, numerous
studies have demonstrated the efficacy of CLZ, including re-
versal of the effects of KETon a social interaction test (Becker
and Grecksch 2004). CLZ blocks the psychotomimetic effects
of KET in patients with schizophrenia (Malhotra et al. 1997).
We used a modified ASST to assess PFC-mediated cognitive
flexibility in mice (Birrell and Brown 2000; Papaleo et al.
2008; Scheggia et al. 2014; Kos et al. 2011). Previous research
has administered acute or sub-chronic NMDAR antagonists;
therefore, we administered similar acute injections of KET
(Kos et al. 2011), as well as applying sub-chronic administra-
tion (McLean et al., 2008). The detailed information can be
provided in the materials and methods section.
The second aim of our study was to assess whether the
effects of CLZ on ASST performance are dose dependent. In
our previous studies using an in vitro model, we demonstrated
the effects of CLZ on D1-D2 receptor heterodimers. The ef-
fect was strongly CLZ concentration dependent; lower con-
centrations, which result in binding to high affinity sites, de-
creased the physical interaction between these two dopamine
sub-receptors, whereas higher concentrations of CLZ in-
creased physical interactions (Faron-Górecka et al. 2008).
Concentration-dependent actions of CLZ were also observed
in studies of 5HT1A-D2 heterodimers (Lukasiewicz et al.
2011). Therefore, we studied two doses of CLZ, and assessed
ASST performance in mice.
Our data may elucidate the complete mechanisms of action
of CLZ and therefore contribute to eliminating the limiting




Experiments were conducted onmale C57Bl/6Jmice (approx-
imately 26 g and 11 weeks of age; Charles-River, Germany).
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Mice were housed in standard laboratory cages under standard
colony conditions (21 ± 2 °C, humidity 40–50%) and on a 12-
h light/dark cycle (lights on at 07:30). Mice were housed in
five per cage with mild food deprivation (2.9 g of food pellets
per day) and ad libitum access to water for 2 weeks before the
test. Food deprivation was crucial because mice at 85% of
their initial body weight would eagerly feed from containers
to obtain the food reward. Breeding five mice per cage was
our limitations; however, according to our experience, sup-
pling five pieces of approx. 2.9 g food pellet into one cage
leads to appropriate reduction of mice weight within 14 days
i.e. weight range for the mice at the beginning of food depri-
vations was 24.5–27.5 g and for the end of the 14-day-period
of food restriction the weight range was 20.0–23.5 g. The
experiments were approved by the Ethics Committee for
Animal Experiments, Institute of Pharmacology, Poland.
Chemicals
KET (10% aqueous solution of 115.34 mg/mL, Biowet,
Poland) was dissolved in saline (SAL) to obtain a concentra-
tion of 100 mg/kg. CLZ (Tocris, UK) was dissolved in 1 M
hydrochloric acid and then diluted in SAL. NaOH solution
was added to buffer the solution to ∼pH 6.5–7.0.
Experiments were conducted using two different paradigms:
acute and sub-chronic administration. For the acute paradigm,
drugs (SAL, KET, and/or CLZ at 0.3 mg/kg; intraperitoneally,
i.p.) were administrated 1 h before start of the ASST, on each
test day. For the sub-chronic paradigm, drugs (KET or SAL)
were repeatedly administrated (i.p.) for 7 consecutive days,
followed by replacement with CLZ (0.3 or 1 mg/kg; i.p.) for
the next 7 days. All injections were done once per day during
this period. The ASST was performed following 14 days of
treatment.
General rules of the ASST
The ASST was conducted as described by Kos et al. (2011).
The apparatus was constructed from black plywood and had a
wire grid floor. It consisted of a larger waiting compartment
and two equally sized choice compartments, which were
accessed through sliding doors. There was a bowl of water
in the waiting compartment, whereas there were containers
with food rewards covered by a layer of digging medium in
the choice compartments. The containers with food rewards
differed from each other based on the digging media and
odours on the outer wall of the containers (Table 1).
ASST procedure
The ASST procedure consisted of 7 days of adaptation to
the new place, 14 days of food restriction with handling,
habituation performed during 1 day, and 2 days of test
(Heisler et al. 2015; Kos et al. 2011). Habituation typically
occurred 1 or 2 days before testing, and testing occurred on
two consecutive days. Habituation involved five phases of
adaptation. During the first phase, mice were habituated to
the testing area by spending 5 min in the waiting compart-
ment. In the next four phases, mice were trained to dig in
pots filled with sawdust, in order to retrieve a food reward.
Mice started each of the four phases in the waiting com-
partment, and the sliding door was then raised to allow
entry to the test compartments containing the pots with
food rewards. In the second phase, mice ate food rewards
placed at the bottom of empty containers. During the third
phase, food rewards were placed on top of a thin layer of
sawdust, and in the fourth phase the rewards were covered
by a thin layer of sawdust. During the fifth phase, the
reward was covered by a thicker layer of sawdust
(∼2 cm). All phases, except for phase 5, consisted of two
trials of the mouse eating a food reward from each of the
two containers. The fifth phase included three trials.
The first test day began with adaptation to the apparatus
and a brief reminder (repetition of the fifth phase of habit-
uation), followed by the five different phases of the task:
(Avery and Krichmar 2015) simple discrimination (SD),
(Barnett et al. 2010) compound discrimination (CD),
(Baviera et al. 2008) compound discrimination reversal
(CDR), (Becker and Grecksch 2004) intra-dimensional
shift (IDS), and (Becker et al. 2003) intra-dimensional shift
reversal (IDSR). Each phase consisted of three training free
trials and several test trials, which varied depending on
whether mice chose the correct container. During training,
the door remained open even if the choice was incorrect,
and the mouse may then have investigated and collected
the food reward from the opposite container. Free trails
were not scored, and the results from these free trails were
not taken into consideration in the presented results.
However, during the test, incorrect choices were recorded
as errors, the door was closed, and the trial was terminated.
In order to complete each phase, mice had to reach a cri-
terion of eight correct discriminations out of ten consecu-
tive trials. Wrong discrimination was considered as dig-
ging in medium—just having a look was not recognize as
mistake. The second test day consisted of four different
phases: (Avery and Krichmar 2015) intra-dimensional shift
2 (IDS2), (Barnett et al. 2010) intra-dimensional shift re-
versal 2 (IDSR2), (Baviera et al. 2008) extra-dimensional
shift (EDS), and (Becker and Grecksch 2004) extra-
dimensional shift reversal (EDSR). The phases for both
test days are described in Table 2. At the beginning of each
discrimination, dust of food reward (chocolate balls) was
sprinkled over all pots to avoid a scent cue from the food
reward. The order of exemplar medium-odour pairings was
counterbalanced; the equal number of mice began the test
from set 1, set 2, set 3, set 4 of medium-odour pairing.
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Locomotor activity test
Locomotor activity was measured individually for eachmouse
using OPTO-M3 locomotor activity cages (Columbus
Instruments, Columbus, OH, USA) attached to a compatible
personal computer. Each cage (13 × 23 × 15 cm) was connect-
ed to an array of photocell beams. Each photobeam interrup-
tion was recorded as horizontal activity, which comprised the
ambulation scores. The experimental design for locomotor
activity measurements was the same as described for the
ASST; however, different animals completed the locomotor
activity test and the ASST.
Data analyses
The number of trials to reach criterion in each phase was
calculated for each mouse, as well as the number of errors in
each phase and duration of time required to complete each
phase. Presented results do not include free trials; however,
analysing data, taking into consideration this training trial,
shows an ID/ED difference in the control group. Statistical
analyses for all behavioural tests were performed using two-
way ANOVA with post hoc multiple comparison tests
(GraphPad Prism 7.0, San Diego, CA).
Results
Locomotor activity
Analyses of locomotor activity after acute treatment revealed a
significant interaction between time (5 min intervals for a total
of 30 min) and drug treatment (SAL, KET, CLZ 0.3 mg/kg,
KET+CLZ 0.3 mg/kg, CLZ 1 mg/kg, KET+CLZ 1 mg/kg)
[F(30,168)] = 2.09, p < 0.01. There were also significant main
effects of time [F(6,168)] = 29.11, p < 0.0001 and drug treatment
[F(5,168)] = 30.35, p < 0.0001. Multiple comparison tests indi-
cated that there was a significant decrease in locomotor activity
at all time points for the KET+CLZ 1 mg/kg group (Fig. 1a).
Two-way ANOVA of the sub-chronic treatment data found no
interaction between time and drug treatment [F(30,168)] = 0.58,
ns, although significant main effects occurred for time
[F (6,168)] = 10.64, p < 0.0001 and drug treatment
[F(5,168)] = 3.84, p < 0.01. However, post hoc analyses did
Table 2 Description of
attentional set-shift task (ASST)
phases
First test day
SD Discrimination on 1 dimension only—digging media; 1 medium is correct, e.g. fine gravel
CD Correct digging medium is the same as for SD, e.g. fine gravel; additional dimension, odour,
is introduced but is irrelevant (e.g. grapefruit and pine)
CDR Correct digging medium is the other medium from the same pair of media, e.g. beads; odour
is still irrelevant
IDS Relevant dimension is still the digging medium and odour is irrelevant; the correct medium
is the same as for the next set of digging medium and odour, e.g. corkboard
IDSR Correct digging medium is the other medium from the same pair of media, e.g. aluminium balls;
odour is still irrelevant
Second test day
IDS2 Relevant dimension is still the digging medium and odour is irrelevant; the correct medium is the
same as for the next set of digging medium and odour, e.g. cardboard
IDSR2 Correct digging medium is the other medium from the same pair of media, e.g. plastic;
odour is still irrelevant
EDS Relevant dimension is odour and digging medium is irrelevant; correct scent is a scent from an
odour pair derived from a set of 4, e.g. peach
EDSR Correct scent is the other odour from the same pair of odours, e.g. rosemary. Digging medium is
irrelevant
Direction of shift was not counterbalanced, and shift from medium to odour is the only shift direction used
SD simple discrimination, CD compound discrimination, CDR compound discrimination reversal, IDS intra-
dimensional shift, IDSR intra-dimensional shift reversal, IDS2 intra-dimensional shift, day 2, IDSR2 intra-
dimensional shift reversal, day 2, EDS extra-dimensional shift, EDSR extra-dimensional shift reversal
Table 1 Types of digging media and odours used in the attentional set-shift task (ASST)
Set 1 Set 2 Set 3 Set 4
Digging medium Fine gravel vs beads Corkboard vs aluminium balls Cardboard vs plastic Bamboo sticks vs polystyrene
Odour Grapefruit vs pine Green tea vs coconut Clove vs cherry Peach vs rosemary
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not indicate any significant differences between individual
groups. Furthermore, we did not observe significant differ-
ences between the SAL and KET groups in either experiment
(Fig. 1b).
ASST performance
In total, 80 mice were successfully trained and tested. Mice
that did not learn the ASST within 25 trials were not in-
cluded in the statistical analyses. The treatment groups for
the acute experiment were the following: SAL (n = 7),
KET (n = 9), CLZ 0.3 mg/kg (n = 7), and KET+CLZ
0.3 mg/kg (n = 8). For the sub-chronic experiment, the
following groups were examined: SAL+SAL (n = 8),
KET+SAL (n = 9), CLZ 0.3 mg/kg (n = 8), KET+CLZ
0.3 mg/kg (n = 7), CLZ 1 mg/kg (n = 8), and KET+CLZ
1 mg/kg (n = 9). Drug treatment did not have any effect on
performance during habituation or training. For acute treat-
ment experiments, two-way ANOVA (drug treatment:
SAL, KET, CLZ 0.3 mg/kg, KET+CLZ 0.3 mg/kg × set
shifting phase: SD, CD, CDR, IDS, IDSR, IDS2, IDSR2,
EDS, EDSR) demonstrated a significant interaction
[F(24,234)] = 1.701, p < 0.05, as well as significant main
effects of the set-shifting phase [F(8,234)] = 2.046, p < 0.05,
and drug treatment [F(3,234)] = 7.662, p = 0.0001. Post hoc
multiple comparison tests revealed significant differences
in a crucial phase of cognitive impairment, EDS, between
KET and KET+CLZ 0.3 mg/kg treatments. KET adminis-
tration significantly increased the number of trials to crite-
rion compared to SAL and CLZ 0.3 mg/kg (from 10 ± 0.73
for SAL and 9.43 ± 0.43 for CLZ to 14.78 ± 1.60 for KET).
This deficit was significantly attenuated by combined
treatment with KET+CLZ 0.3 mg/kg (9.57 ± 0.68,
p < 0.05) (Fig. 2).
We also observed significant changes in the EDS phase
following sub-chronic KET, although these changes were
reduced compared to those following a single administra-
tion of KET (from 10 ± 0.5 to 12.78 ± 1.29, p < 0.05; t
test). Two-way ANOVA revealed no significant interaction
between drug treatment (SAL, KET, CLZ 0.3 mg/kg,
KET+CLZ 0.3 mg/kg, CLZ 1 mg/kg, KET+CLZ 1 mg/
kg) and set-shifting phases (SD, CD, CDR, IDS, IDSR,
IDS2, IDSR2, EDS, EDSR) [F ( 40 , 387 ) ] = 1.299,
p = 0.112. There was also no main effect of the set-
shifting phase [F(8,387)] = 0.921, p = 0.499. Two-way
ANOVA demonstrated a significant main effect of drug
treatment [F(5,387)] = 12.54, p < 0.0001. Administration
of 1 mg/kg CLZ to KET-treated mice induced deficits in
the EDS phase (p < 0.01) compared to 1 mg/kg CLZ ad-
ministration in the absence of KET (trials to criterion CLZ
1 mg/kg = 8.75 ± 0.42, KET+CLZ 1 mg/kg = 15.22 ± 1.96),
whereas the lower dose of CLZ (0.3 mg/kg) significantly
Fig. 1 a The effect of acute (1 h
before locomotor activity testing)
treatment on locomotor activity in
mice. Data presented as
mean ± S.E.M. activity counts
over a 30-min test in 5-min
periods. Significant changes were
observed in the KET 20 mg/kg +
CLZ 1mg/kg group vs the control
group (SAL), *p < 0.05,
**p < 0.01, ***p < 0.0001. b The
effect of sub-chronic treatment on
locomotor activity in mice.
Behavioural test of Locomotor
Activity was made 24 h after last
treatment. Data presented as
mean ± S.E.M. activity counts
over a 30-min test in 5-min
periods. No significant difference
between the groups was observed
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decreased EDS phase deficits in KET-treated mice (from
12.78 ± 1.29 to 9.43 ± 0.42, p < 0.01) (Fig. 3).
Discussion
The main aim of the present study was to assess whether
CLZ reduces KET-induced deficits, using the ASST in a
mouse model. Since both NMDAR antagonists and CLZ
affect locomotor activity, we first examined the effects of
KET and CLZ using a locomotor activity test. Studies
assessing locomotor activity and novel object recognition
(NOR) following administration of NMDAR antagonists
indicate that 5-HT2AR antagonism, 5-HT1AR agonism,
and 5-HT6R and 5-HT7R antagonism contribute to atten-
uating NMDAR antagonist-induced increases in locomotor
activity, and also reverse impairments in NOR after acute
or long-term treatment with NMDAR antagonists (Meltzer
et al. 2011; McOmish et al. 2012). The present study found
decreased locomotor activity with the interaction of KET
and CLZ at a higher dose (1 mg/kg). CLZ has high affinity
for 5HT2ARs; therefore, the observed effect may result
from CLZ and KET activity at this receptor. In studies
using the NMDAR antagonist, MK-801, CLZ was admin-
istered at a low dose (0.2 mg/kg; subcutaneous, s.c.), be-
cause higher doses produced disturbances in locomotor
activity (Hoffman and Basurto 2014). We did not observe
any statistically significant changes in locomotor activity
after acute administration of KET (20 mg/kg) combined
with CLZ (0.3.mg/kg). However, since locomotor effects
were observed after administration of acute KET 20 mg/
kg + CLZ 1 mg/kg, locomotor activity was assessed 24 h
after the last dose of drugs in the sub-chronic administra-
tion paradigm; we did not observe any changes in locomo-
tor activity. The design of our ASST experiments was
based on this observation. The higher dose of CLZ
Fig. 3 The effect of sub-chronic treatment of KET (20 mg/kg) and CLZ
(0.3 or 1 mg/kg) on trials to reach criterion in attentional set shift task.
Data are presented as mean ± S.E.M and were analysed using two-way
ANOVA and post hoc multicomparison test. *p < 0.05 compared KET vs
SAL, #p < 0.01 compared KET+CLZ 1 mg/kg vs CLZ 1 mg/kg and
$p < 0.01 compared KET+CLZ 0.3 mg/kg vs KET in the EDS phase
Fig. 2 The effect of acute (1 h before ASST) treatment of KET
(20 mg/kg) and CLZ (0.3 mg/kg) on trials to reach criterion in
attentional set shift task. Data are presented as mean ± S.E.M and were
analysed using two-way ANOVA and post hoc multi comparison test.
*p < 0.05 compared KET 20 mg/kg vs all groups in CDR, IDSR2, and
EDS phase
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(1 mg/kg) was eliminated after acute administration, since
complete blockade of locomotor activity (1 h after drug
administration) impaired the ability to complete the
ASST experimental paradigm. Mice should be fully func-
tioning while completing the tasks, and deficits in cogni-
tive symptoms induced by KET are observed after 50 min
of KET treatment (Kos et al. 2011). Our ASST results
demonstrate that a single administration of KET caused
disturbances in the EDS phase, which reflects cognitive
disruption. The dose of KET (20 mg/kg) was selected
based on Kos et al. 2011, who found that this dose pro-
duces maximal effects in the EDS phase.
In the present study, mice were unable to perform all tests,
including SD, CD, CDR, IDS, IDSR, EDS, and EDSR in
1 day; therefore, the ASST occurred over 2 days. In addition,
our experimental paradigm included two other sessions, IDS2
and IDSR2, similarly to the procedure described by Kos et al.
(2011). These authors found that the additional phases en-
hance a set of cognitive deficits and produce overall improve-
ments from CD to IDSR2, in addition to deterioration during
the crucial phase for cognitive impairment, EDS (Garner et al.
2006; Kos et al. 2011).
Our results indicate that saline-treated mice required simi-
lar number of trials to reach criterion to complete the IDS and
EDS phases, which might indicate that an attentional set had
not been formed.We decided to present results without includ-
ing free trials because according to literature, authors of many
papers did not score the free trials and show ASST results
which do not include training trials (Nikiforuk et al. 2015;
Heisler et al. 2015; McLean et al. 2008). However, at the
beginning, we analysed ASST results taking into account free
trials and we observed an ID/ED difference in the control
group [mean ± S.E.M. respectively: 12 ± 0.5 vs 13 ± 0.73].
Based on these results, we regarded the ASST procedure as
implemented well, and although results without including free
trials did not show that ED reflects a ‘cost’ of shifting atten-
tional set from one dimension to another in the control group,
we recognized that we can interpret effects of various
ketamine/clozapine dosing regimens on ED performance as
an effect on attentional set-shifting. In these free trials, mice
were allowed to explore both containers regardless of whether
they find food reward or not, and this was time for them to
learn what cue is relevant. This may explain lack of significant
EDS and reversal impairments in the control group because
these mice did not have any cognitive deficits and free trails
were sufficient to shift their attentional set. It is possible that
saline-treated mice learned the EDS rule within these three
free trials; thus, they did not need more trails to reach the
criterion; this may also explain the occurrence of minimum
trials to criterion without any apparent errors in certain dis-
criminations. The same issue has been discussed by McLean
et al. (2008). To eliminate the possibility that mouse follows
the smell of the hidden food pellets, we sprinkled dust of food
pellet over all pots few times during each stage; therefore, we
were sure that we avoid scent cue from food reward.
Moreover, we took care of a thick layer of medium in con-
tainers—in the ASST test, we used glass crystallizers filled to
three quarters height by medium which completely prevented
getting out of odour. However, regardless of free trails in our
ASST procedure, we observed a significant increase in trials
required to reach criterion in ketamine-treated mice in the
EDS stage, suggesting that acute and sub-chronic ketamine
causes a selective deficit in attentional set-shifting ability.
Our data confirm the results presented by Kos et al. (2011)
demonstrating that, in the mouse model of ASST, KET pro-
duced specific deficits in cognitive flexibility after a single
dose given 50 min before the test. In our studies, we observed
this effect after 60 min of treatment. In the case of chronic
treatment, there was data concerning chronic treatment with
KET; however, our observations are consistent with results
obtained with different NMDA antagonists (PCP) in mice
(Scheggia et al. 2014) or chronic KET in rats (Nikiforuk and
Popik 2012).
Single or sub-chronic administrations of KET, PCP, or
MK-801 are often used in animal models of NMDAR
antagonist-induced cognitive disorders. Our data confirm
the results presented by Kos et al. (2011) demonstrating
that, in the ASST mouse model, KET produces specific
deficits in cognitive flexibility after a single dose adminis-
tered 50 min before the test. The present study demonstrat-
ed this effect after 60 min of treatment. The main finding of
the present work is that CLZ, at a dose of 0.3 mg/kg,
reversed the effect of KET after both acute and sub-
chronic treatments. We have therefore provided the first
demonstration of the effect of CLZ on KET-induced
alterations in an ASST paradigm.
CLZ has previously been tested using set-shifting tasks
in rats, rabbits, or mice, in relation to cognitive deficits
induced by MK-801 or PCP. CLZ (5 mg/kg) significantly
reversed the effects of MK-801 in rats (Jones et al. 2014).
CLZ (0.63 mg/kg, s.c.) also reversed PCP-induced
cognitive deficits in Morris’ water maze, although the
highest dose (1.3 mg/kg) did not produce significant
effects (Didriksen et al. 2007). Furthermore, CLZ
(0.5 mg/kg) prevented PCP-induced cognitive impairments
(Beraki et al. 2008), and at a lower dose (0.2 mg/kg, s.c.) it
also prevented MK-801-induced deficits in a NOR test in
rabbits (Hoffman and Basurto 2014). These results are con-
sistent with our data indicating that lower doses of CLZ
impact the effects of NMDAR antagonists. Our weak effect
of KET in the sub-chronic paradigm may have resulted
from the length of administration; however, relevant data
regarding NMDAR antagonist administration do not
enable definitive conclusions. Rat studies have found that
KET treatment for 10 days is required to induce long-term
cognitive impairments (Nikiforuk and Popik 2012).
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However, PCP administered to rats twice daily for 7
consecutive days affects the EDS phase of the ASST after
a 10-day washout period (McLean et al. 2008). Although
Enomoto and Floresco (2009) reported that 5 days of KET
administration was insufficient to induce deficits, other
research has found that a 5-day treatment with KET
induced changes in social behaviour and latent inhibition
in rats (Becker et al. 2003). Despite no effects of sub-
chronic KET (the effect of acute KET treatment was
greater), CLZ 0.3 mg/kg can reverse the effects of KET,
whereas a higher dose of CLZ potentiates the effects of
KET.
The present findings indicate that the dose of CLZ must
be considered in studies of cognitive deficits, as dose depen-
dency occurs, by which CLZ can potentiate (higher dose) or
attenuate (lower dose) the effects of KET. In addition, the
mechanisms of CLZ-induced changes to KET-induced
cognitive deficits have not been elucidated. Connectionist
models have demonstrated that the cognitive symptoms of
schizophrenia result from dopaminergic neurons altering the
gain of activity in working memory (Cohen and Servan-
Schreiber 1992; Braver and Cohen 1999). In contrast,
instabilities in cortical attractor states can produce the
symptoms of schizophrenia (Rolls et al . 2008).
Furthermore, increasing or decreasing dopamine neurotrans-
mission using dopaminergic agents potentiates or attenuates
KET-induced amnesia in a model of cognition. These data
suggest a possible interaction between the NMDA and do-
paminergic systems in behavioural and cognitive responses
(Farahmandfar et al. 2016). The mechanism underlying
these changes may be an imbalance of dopamine D1/D2
receptors, which can alter NMDA and GABA conductance
(Avery and Krichmar 2015). We observed a dose-dependent
effect of CLZ in KET-treated mice; a lower dose of CLZ
reversed the effects of KET, whereas a higher dose enhanced
the effects. Such findings may be related to an imbalance of
dopamine receptors. Our previous study using an in vitro
model demonstrated that a lower dose of CLZ (acting on
dopamine receptors in high affinity states, which are the
active state of receptors) uncoupled D1-D2 heterodimers,
whereas a higher dose of CLZ increased D1-D2
heterodimerization; these scenarios produced different
effects on the intracellular signalling pathway involving
phospholipase C-mediated calcium mobilization (Faron-
Górecka et al. 2008).
The dose-dependent effects of CLZ observed in the
present study may also result from action at serotonin
5HT2A receptors, thereby contributing to attenuation of
cognitive deficits induced by KET. Previous research has
suggested that strong 5HT2A receptor antagonism, com-
bined with weak dopamine D2 receptor antagonism, is
the principal pharmacologic feature that differentiates clo-
zapine from other atypical antipsychotic drugs (APDs) and
from typical first-generation APDs (Meltzer et al. 2011).
This interpretation is supported by data demonstrating that
Akt phosphorylation via 5HT2A receptors is required for
CLZ efficacy in blocking MK-801 and PCP-induced
models of schizophrenic behaviours in mice (Schmidt
et al. 2014). These data indicate that CLZ acts as an agonist
at 5HT2A receptors. Although higher doses of CLZ pro-
duce antagonistic effects at 5HT2A receptors, it is possible
that lower doses of CLZ promote Akt phosphorylation via
5HT2A-D2 receptor heterodimers. The potential for these
two receptors to dimerize has been demonstrated by
Łukasiewicz et al. (2010).
Our study is not without limitations, e.g. the lack of a
significant impairment in performance of vehicle-treated
animals from the IDS to the EDS phase. The use of three
free trials, as previously mentioned, before each new phase
of the task is an explanation for this. A similar effect was
observed by McLean et al. (2008) in rats. Also, having used
only two doses of CLZ is another limitation; a dose response
should ideally have been conducted; however, as in our pre-
vious in vitro studies, we decided to use only these two doses.
A further limitation of the current experimental design was the
decision not to counterbalance the dimension shifts, i.e. all the
mice were switched from medium to odour. The same issue
has been discussed by McLean et al. (2008). Another aspect
which could have been a potential weakness was the digging
media pairings.
Conclusion
The present data indicate that CLZ dose-dependently reverses
KET-induced cognitive deficits. These behavioural results
should be further investigated using biochemical studies, in
order to assess whether dose dependence corresponds to
mechanisms at different receptors. Specifically, the contribu-
tions of monomeric receptor states and heterocomplexes
should be considered.
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